欧菲光(002456.SZ)18亿人币转让安徽精卓逾51%股权 聚焦光学核心业务
欧菲光(002456.SZ)公布,公司及全资子公司欧菲光科技、控股子公司欧菲光学和控股子公司欧菲触控共同出资设立安徽精卓。公司及欧菲光科技、欧菲光学、欧菲触控拟与安徽鼎恩签署股权转让协议,欧菲光科技、欧菲光学、欧菲触控拟将持有的部份安徽精卓股权转让给安徽鼎恩,转让後安徽鼎恩将持有安徽精卓51.88%的股份,股权转让总金额为18亿元人民币。
公司表示,该交易有利於公司优化资源配置及财务结构,聚焦光学核心业务。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.